On October 12, 2020, multibillion-dollar specialty pharmaceutical company Mallinckrodt plc and several affiliates filed a petition for relief under Chapter 11 of the Bankruptcy Code in the Bankruptcy Court for the District of Delaware (Case 20-12521). The company reports $1 billion to $10 billion in both assets and liabilities. A link to the Mallinckrodt petition can be found here. Mallinckrodt issued a press release stating that it had entered into a restructuring support agreement with key stakeholders, including holders of approximately 84% of the company’s guaranteed unsecured notes and certain governmental entities, including 50 states and territories, and a court-appointed plaintiff’s executive committee representing the interests of thousands of opioid plaintiffs.
Cole Schotz does not represent the Debtor in this case. We are posting this for informational purposes only. If you have received a notice and have any questions, you should contact Debtor’s counsel.
Cole Schotz’s nationally renowned Bankruptcy & Corporate Restructuring group practices in Delaware, Maryland, New Jersey, New York, and Texas.